Targeted Medical Pharma Reports Preliminary Data on Red Blood Cell Stimulating Formulation

LOS ANGELES--()--Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, today unveiled preliminary data indicating that its new amino acid oral formulation stimulated red blood cell and platelet development during an investigational study.

Initial results showed that the company’s new amino acid based formulation increased red blood cell counts, including reticulocytes, the precursors of red blood cells, as well as hemoglobin and hematocrit. The study also found a 30 percent rise in circulating platelets after seven days, as well as a 16 percent increase in hemoglobin and a 450 percent increase in peripheral reticulocytes (p<0.01).

“We are thrilled that our new orally administered formulation increased the number of red blood cells in patients, emphasizing the need for the initiation of further studies,” said William Shell, M.D., CEO of Targeted Medical Pharma, Inc. and lead scientist of the study. “What’s truly a benefit is that our formulation produces similar results as an approved injected medication.”

The company noted that its new amino acid based formulation can potentially be used to manage anemia related to a variety of chronic diseases.

Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, pharmacies and skilled nursing facilities for the treatment of chronic disease including pain syndromes, obesity, and sleep and cognitive disorders. Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are sold in the United States and Japan. The company manufactures nine proprietary medical foods, as well as 48 convenience pack kits, which pair a medical food and branded or generic pharmaceutical. These prescription medications and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.

Contacts

PondelWilkinson
George Medici, gmedici@pondel.com
Ron Neal, rneal@pondel.com
310-279-5980

Contacts

PondelWilkinson
George Medici, gmedici@pondel.com
Ron Neal, rneal@pondel.com
310-279-5980